{
    "id": 29511,
    "fullName": "SLC34A2 over exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "SLC34A2 over exp indicates an over expression of the Slc34a2 protein and/or mRNA. However, the mechanism causing the over expression is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 10568,
        "geneSymbol": "SLC34A2",
        "terms": [
            "SLC34A2",
            "NAPI-3B",
            "NAPI-IIb",
            "NPTIIb",
            "PULAM"
        ]
    },
    "variant": "over exp",
    "createDate": "03/04/2019",
    "updateDate": "03/04/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 16226,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, treatment with DNIB0600A (lifastuzumab vedotin) compared to treatment with Doxil (pegylated liposomal doxorubicin) resulted in an improved progression-free survival (5.3 mo vs 3.4 mo) and objective response rate of 36% (15/42) vs 14% (6/43), respectively, in platinum-resistant ovarian cancer patients overexpressing Slc34a2 (PMID: 29401246; NCT01991210).",
            "molecularProfile": {
                "id": 31549,
                "profileName": "SLC34A2 over exp"
            },
            "therapy": {
                "id": 1345,
                "therapyName": "DNIB0600A",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14352,
                    "pubMedId": 29401246,
                    "title": "Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29401246"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        }
    ],
    "molecularProfiles": [
        {
            "id": 31549,
            "profileName": "SLC34A2 over exp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}